BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29648968)

  • 1. Saccharina japonica Extract Suppresses Stemness of Glioma Stem Cells by Degrading Epidermal Growth Factor Receptor/Epidermal Growth Factor Receptor Variant III.
    Kim SY; Kim JY; Shin WS; Lee SJ; Chi SG; Lee JY; Park MJ
    J Med Food; 2018 May; 21(5):496-505. PubMed ID: 29648968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emodin suppresses maintenance of stemness by augmenting proteosomal degradation of epidermal growth factor receptor/epidermal growth factor receptor variant III in glioma stem cells.
    Kim J; Lee JS; Jung J; Lim I; Lee JY; Park MJ
    Stem Cells Dev; 2015 Feb; 24(3):284-95. PubMed ID: 25229646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARK7 maintains the stemness of glioblastoma stem cells by stabilizing epidermal growth factor receptor variant III.
    Kim JY; Kim HJ; Jung CW; Choi BI; Lee DH; Park MJ
    Oncogene; 2021 Jan; 40(3):508-521. PubMed ID: 33188296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of Src and PLK1 regulate stemness and induce apoptosis through Notch1-SOX2 signaling in EGFRvIII positive glioma stem cells (GSCs).
    Li X; Tao Z; Wang H; Deng Z; Zhou Y; Du Z
    Exp Cell Res; 2020 Nov; 396(1):112261. PubMed ID: 32896567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ANO1 regulates the maintenance of stemness in glioblastoma stem cells by stabilizing EGFRvIII.
    Kim HJ; Kim JY; Jung CW; Lee YS; An JY; Kim EH; Kim KH; Lee SP; Park JY; Park MJ
    Oncogene; 2021 Feb; 40(8):1490-1502. PubMed ID: 33452454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation of glioblastoma multiforme stem-like cells leads to downregulation of EGFR and EGFRvIII and decreased tumorigenic and stem-like cell potential.
    Stockhausen MT; Kristoffersen K; Stobbe L; Poulsen HS
    Cancer Biol Ther; 2014 Feb; 15(2):216-24. PubMed ID: 24525857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles.
    Kaluzova M; Bouras A; Machaidze R; Hadjipanayis CG
    Oncotarget; 2015 Apr; 6(11):8788-806. PubMed ID: 25871395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of estrogen receptor beta signaling reduces stemness of glioma stem cells.
    Sareddy GR; Pratap UP; Venkata PP; Zhou M; Alejo S; Viswanadhapalli S; Tekmal RR; Brenner AJ; Vadlamudi RK
    Stem Cells; 2021 May; 39(5):536-550. PubMed ID: 33470499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells.
    Kim RK; Kim MJ; Yoon CH; Lim EJ; Yoo KC; Lee GH; Kim YH; Kim H; Jin YB; Lee YJ; Cho CG; Oh YS; Gye MC; Suh Y; Lee SJ
    Mol Pharmacol; 2012 Sep; 82(3):400-7. PubMed ID: 22648970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Xihuang Pill-destabilized CD133/EGFR/Akt/mTOR cascade reduces stemness enrichment of glioblastoma via the down-regulation of SOX2.
    Xu L; Duan H; Zou Y; Wang J; Liu H; Wang W; Zhu X; Chen J; Zhu C; Yin Z; Zhao X; Wang Q
    Phytomedicine; 2023 Jun; 114():154764. PubMed ID: 36963368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morusin inhibits glioblastoma stem cell growth in vitro and in vivo through stemness attenuation, adipocyte transdifferentiation, and apoptosis induction.
    Guo H; Liu C; Yang L; Dong L; Wang L; Wang Q; Li H; Zhang J; Lin P; Wang X
    Mol Carcinog; 2016 Jan; 55(1):77-89. PubMed ID: 25557841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
    Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
    Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
    Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
    Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suberoylanilide hydroxamic acid represses glioma stem-like cells.
    Hsu CC; Chang WC; Hsu TI; Liu JJ; Yeh SH; Wang JY; Liou JP; Ko CY; Chang KY; Chuang JY
    J Biomed Sci; 2016 Nov; 23(1):81. PubMed ID: 27863490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway.
    Sai K; Wang S; Balasubramaniyan V; Conrad C; Lang FF; Aldape K; Szymanski S; Fokt I; Dasgupta A; Madden T; Guan S; Chen Z; Alfred Yung WK; Priebe W; Colman H
    J Neurooncol; 2012 May; 107(3):487-501. PubMed ID: 22249692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tanshinone IIA inhibits the growth, attenuates the stemness and induces the apoptosis of human glioma stem cells.
    Yang L; Guo H; Dong L; Wang L; Liu C; Wang X
    Oncol Rep; 2014 Sep; 32(3):1303-11. PubMed ID: 24970314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A minority subpopulation of CD133(+) /EGFRvIII(+) /EGFR(-) cells acquires stemness and contributes to gefitinib resistance.
    Liu XJ; Wu WT; Wu WH; Yin F; Ma SH; Qin JZ; Liu XX; Liu YN; Zhang XY; Li P; Han S; Liu KY; Zhang JM; He QH; Shen L
    CNS Neurosci Ther; 2013 Jul; 19(7):494-502. PubMed ID: 23575351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.